ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3147

Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease

Janalee Taylor1, Edward H. Giannini1, Daniel Lovell2 and Esi M. Morgan DeWitt1, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Assessment, Disease Activity, juvenile idiopathic arthritis (JIA), pediatric rheumatology and physician data

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: ACR/ARHP Combined Abstract Session: Pediatric Rheumatology

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: With the advent and implementation of advanced drug therapy clinical inactive disease (CID) has become an attainable target in the treatment of juvenile idiopathic arthritis (JIA).   As a result CID is becoming an endpoint in clinical trials and a goal of quality improvement efforts.  The ACR Provisional Criteria that describe CID include the physician/provider’s global assessment (PGA), which must be scored as zero on a scale of 0 (indicating no disease activity) to 10 (most disease activity) or ≤ 1 when using the Juvenile Arthritis Disease Activity Score.  Scoring of the PGA is not standardized and considerable inter-provider variation is known to exist.  Our goal was to measure the degree of this variation when scoring patients who were known to meet the ACR provisional criteria of CID, (intended for systemic, oligo- and polyarthritis) and determine clinical and/or laboratory parameters that contribute most to the non-uniformity in the assessment of the PGA in clinical practice.

Methods: Twenty patient profiles from the JIA registry at Cincinnati Children’s Hospital Medical Center (CCHMC) who met the ACR provisional criteria for CID were given to a total of 51 providers who were members of the clinical faculty of the Rheumatology division of CCHMC, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), or of the Pediatric Rheumatology –  Care and Outcomes Improvement Network (PR-COIN).  Using Delphi questionnaire and nominal group techniques for consensus building we determined the intra-class correlation (ICC) for the entire provider group, and asked what variables most strongly influenced their scoring of the PGA. 

Results:   The twenty cases included systemic 0, oligoarthritis 6, polyarthritis 7, psoriatic 3, ERA 3, arthritis associated with IBD 1.  Two patients had uveitis.  A total of 51 providers participated in the exercise with a total of 1022 PGA scores.   The ICC was 0.15.  The standard deviation (SD) due to patient differences was 0.127, and SD due to different raters of the patients was 0.697, suggesting that differences in physician-ratings accounted for most of the variability.    Variables that influenced scoring were presence of pain, questionable TMJ involvement, joint loss of motion, morning stiffness, psoriasis, and past history of uveitis.

Conclusion: Combined data from 3 groups of experienced pediatric rheumatologists reveal that substantial variation in scoring the PGA continues to exist when scoring JIA patients with very low disease activity.  JIA is a heterogeneous collection of conditions, with various extra-articular manifestations that providers consider in making assessments.  Due to the complexity of the conceptual framework of the PGA, standardization is likely not feasible.  This implies that other disease states, other than CID, that do not require the PGA to equal zero may be more suitable for clinical trial endpoints and when setting goals of quality improvement efforts.


Disclosure: J. Taylor, None; E. H. Giannini, AbbVie, 5; D. Lovell, AbbVie Inc., AstraZeneca, Centocor, Bristol-Myers Squibb, Pfizer, Regeneron, Hoffman La-Roche, Novartis, UBC, Xoma, and Genentech, 9; E. M. Morgan DeWitt, None.

To cite this abstract in AMA style:

Taylor J, Giannini EH, Lovell D, Morgan DeWitt EM. Inter-Provider Reliability in Scoring the Physician Global Assessment of Disease Activity Among Patients with Juvenile Idiopathic Arthritis Patients Who Met the ACR Provisional Criteria for Clinical Inactive Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/inter-provider-reliability-in-scoring-the-physician-global-assessment-of-disease-activity-among-patients-with-juvenile-idiopathic-arthritis-patients-who-met-the-acr-provisional-criteria-for-clinical-i/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inter-provider-reliability-in-scoring-the-physician-global-assessment-of-disease-activity-among-patients-with-juvenile-idiopathic-arthritis-patients-who-met-the-acr-provisional-criteria-for-clinical-i/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology